Published on

December 10, 2018

Last updated on

March 11, 2026

Approval of Clinically Urgent New Drugs

Pharma & Biotech

Approval of Clinically Urgent New Drugs

On 30.10.2018, the NMPA (former NMPA) issued guidelines for the approval process of clinically urgent new drugs (NMPA No. 79-2018). The product range, selection criteria, review procedure, and requirements for the application documents were specified.

Related News

Two professionals in an office review documentation for a HealthScreen glucose monitor while examining a computer display showing a product label with model number, barcode, and QR code. One person points to the code on the screen as the other reads.

Malaysia Introduces New e-IFU & Digital Labelling Guidance for Medical Devices

Malaysia’s MDA publishes the 7th edition of guidance on medical device labelling, with new e-labelling, e-IFU, and accessibility requirements

Medical Devices

April 1, 2026

Two office professionals sit at a desk in an office reviewing cosmetic and skincare product packaging alongside printed documents and binders. One person examines a product bottle while the other works on a laptop, suggesting regulatory compliance review.

Vietnam Authorities Step Up Cosmetic Recalls as Enforcement Tightens

Vietnam’s Drug Administration (DAV) is stepping up cosmetic product recalls as post-market surveillance tightens.

April 1, 2026

Laboratory scientist wearing a lab coat, protective goggles, gloves, and a blue hair cover carefully examining a small vial of liquid in a modern laboratory. A tray of sample vials sits on the bench in front.

BPOM Clarifies Indonesia–US Trade Agreement Impact on Pharmaceutical Regulation

BPOM confirms pharmaceutical authorization, GMP oversight, and regulatory authority remain unchanged under the Indonesia–US trade agreement.

Pharma & Biotech

April 1, 2026

Contact Our Consultants & Discover How We Can Support You

Let Cisema help turn your plans into reality.